文献速递消化系统肿瘤

阿司匹林使用与肝细胞癌风险的关联

Association Between Aspirin Use and Risk of Hepatocellular Carcinoma.
PubMed 文献 · JAMA Oncol · 2018-01-01

该研究基于美国两项前瞻性队列(护士健康研究和卫生专业人员随访研究)的133 371名参与者,分析阿司匹林使用与肝细胞癌(HCC)风险的关系。结果显示,定期使用阿司匹林(每周≥2片325mg标准剂量)与HCC风险降低相关(调整HR 0.51,95%CI 0.34-0.77),且存在剂量和持续时间依赖性;非阿司匹林NSAIDs则无显著关联。

要点

  • 定期阿司匹林使用与HCC风险降低约一半相关(调整HR 0.51)。
  • 获益呈剂量和持续时间依赖性,使用≥5年者风险更低(HR 0.41)。
  • 非阿司匹林NSAIDs使用与HCC风险无显著关联。

核心结论

  • 定期长期使用阿司匹林与HCC风险呈剂量依赖性降低相关,使用5年以上时明显。
  • 非阿司匹林NSAIDs未显示类似关联。

研究设计与样本

  • pooled分析两项美国前瞻性队列:护士健康研究和卫生专业人员随访研究。
  • 共纳入133 371名医护人员(87 507名女性,45 864名男性),排除基线癌症患者。
  • 随访超过26年,共4 232 188人年,记录108例HCC(65女,43男)。

主要发现

  • 与不定期使用相比,定期使用阿司匹林(每周≥2片325mg标准剂量)与HCC风险降低相关(调整HR 0.51;95%CI 0.34-0.77)。
  • 非阿司匹林NSAIDs使用与HCC风险无显著关联(调整HR 1.09;95%CI 0.78-1.51)。

临床怎么用

  • 对于HCC高风险人群,长期定期使用阿司匹林可能作为一级预防的潜在策略,但需权衡出血风险。
  • 非阿司匹林NSAIDs不推荐用于HCC预防。

局限性

  • 观察性研究设计,不能确立因果关系。
  • HCC病例数较少(108例),可能限制统计效能。
  • 参与者为医护人员,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prospective data on the risk of hepatocellular carcinoma (HCC) according to dose and duration of aspirin therapy are limited. OBJECTIVE: To examine the potential benefits of aspirin use for primary HCC prevention at a range of doses and durations of use within 2 prospective, nationwide populations. DESIGN, SETTING, AND PARTICIPANTS: Pooled analysis of 2 prospective US cohort studies: the Nurses' Health Study and the Health Professionals Follow-up Study. Data were accessed from November 1, 2017, through March 7, 2018. A total of 133 371 health care professionals who reported data on aspirin use, frequency, dosage, and duration of use biennially since 1980 in women and 1986 in men were included. Individuals with a cancer diagnosis at baseline (except nonmelanoma skin cancer) were excluded. MAIN OUTCOMES AND MEASURES: Cox proportional hazards regression models were used to calculate multivariable adjusted hazard ratios (HRs) and 95% CIs for HCC. RESULTS: Of the 133 371 participants, 87 507 were women and 45 864 were men; in 1996, the median time of follow-up, the mean (SD) age was 62 (8) years for women and 64 (8) years for men. Over more than 26 years of follow-up encompassing 4 232 188 person-years, 108 incident HCC cases (65 women, 43 men) were documented. Compared with nonregular use, regular aspirin use (≥2 standard-dose [325-mg] tablets per week) was associated with reduced HCC risk (adjusted HR, 0.51; 95% CI, 0.34-0.77). This benefit appeared to be dose related: compared with nonuse, the multivariable-adjusted HR for HCC was 0.87 (95% CI, 0.51-1.48) for up to 1.5 standard-dose tablets per week, 0.51 (95% CI, 0.30-0.86) for more than 1.5 to 5 tablets per week, and 0.49 (95% CI, 0.28-0.96) for more than 5 tablets per week (P for trend = .006). Significantly lower HCC risk was observed with increasing duration (P for trend = .03); this decrease was apparent with use of 1.5 or more standard-dose aspirin tablets per week for 5 or more years (adjusted HR, 0.41; 95% CI, 0.21-0.77). In contrast, use of nonaspirin nonsteroidal anti-inflammatory drugs was not significantly associated with HCC risk (adjusted HR, 1.09; 95% CI, 0.78-1.51). CONCLUSIONS AND RELEVANCE: This study suggests that regular, long-term aspirin use is associated with a dose-dependent reduction in HCC risk, which is apparent after 5 or more years of use. Similar associations were not found with nonaspirin NSAIDs. Further research appears to be needed to clarify whether aspirin use represents a feasible strategy for primary prevention against HCC.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Simon TG, Ma Y, Ludvigsson JF, et al. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol. 2018. PMID: 30286235. doi:10.1001/jamaoncol.2018.4154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。